Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01727726 · ClinicalTrials.gov registry record · Phase 3
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,182
- Enrollment target
NCT01727726 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 2,182 participants.
The verdict
NCT01727726, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,182 participants
- Enrollment target
Study Summary
To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.
Interventions
- DRUG Placebo
- DRUG Brexpiprazole
- DRUG Seroquel XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,182 participants |
| Start Date | 2012-12 |
| Est. Completion | 2016-11-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01727726
The ClinicalTrials.gov registry entry for NCT01727726 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01727726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01727726 about?
NCT01727726 is a clinical study titled "A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial". To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.
What is the current status of trial NCT01727726?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,182 participants. The study started on 2012-12. Estimated completion is 2016-11-10.
What interventions are being tested in trial NCT01727726?
The interventions under investigation include: Placebo (DRUG), Brexpiprazole (DRUG), Seroquel XR (DRUG).
Who is sponsoring clinical trial NCT01727726?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.